10th Feb 2016 10:08
LONDON (Alliance News) - Verseon Corp on Wednesday said it will present new data for several promising oral anticoagulant drug candidates at an upcoming conference.
The drug discovery company said its candidates represent a "novel class of highly selective direct thrombin inhibitors" with "superior" preclinical bleeding risk profiles when compared to those of the existing novel oral anticoagulants.
The data will be presented on February 25 at the 3rd International Conference on Heart & Brain in Paris.
"The new results we are presenting at ICHB include data from an additional comprehensive preclinical thrombosis model that further confirms the efficacy of Verseon's drug candidates," said Anirban Datta, director of discovery biology at Verseon.
"Our anticoagulants continue to show positive results as the program progresses," Datta added.
Verseon raised USD100 million in its initial public offering in May, when it sold 32.6 million new shares at 202 pence. Shares in Verseon were untraded at 180.00p on Wednesday.
By Samuel Agini; [email protected]; @samuelagini
Copyright 2016 Alliance News Limited. All Rights Reserved.